Dietary interventions for multiple sclerosis-related outcomes
Meta-analysisHumans
- Design
- Meta-analysis
- Subjects
- 30 randomised or controlled trials (41 articles) in adults with multiple sclerosis; palmitoylethanolamide was one of six 'other supplement' trials
- Dose used in the study
- Not stated in the abstract for palmitoylethanolamide
- Duration
- Not stated in the abstract
- What was measured
- Relapses, disability progression, MRI activity, serious adverse events and patient-reported outcomes for dietary interventions versus placebo or another intervention, with Cochrane methods and GRADE certainty
What the authors reported
This meta-analysis found:
- All 30 trials had at least one issue giving unknown or high risk of bias.
- PUFA versus MUFA showed no difference in relapses (RR 1.02, 95% CI 0.88 to 1.20; 217 participants, very low certainty).
- Antioxidants versus placebo also showed no difference (RR 0.98, 0.59 to 1.64; 345 participants, low certainty).
- The authors say evidence is insufficient to show whether antioxidants or other supplements, including PEA, change MS outcomes.
Limits of this study
A Cochrane review; the abstract pools no PEA-specific results, so the single PEA trial's findings are not reported here. Natalie Parks has consulted for and received funds from Biogen, EMD Serono, Roche and Sanofi Genzyme; Bradley Johnston received an institutional start-up grant.
Source
PubMed 32428983 · doi:10.1002/14651858.CD004192.pub4
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.